New hope for chemo patients: drug may stop nerve pain
NCT ID NCT03722680
First seen May 20, 2026 · Last updated May 20, 2026
Summary
This study tests whether the drug riluzole can prevent nerve damage caused by oxaliplatin chemotherapy in people with stage II or III colorectal cancer. About 80 adults will receive either riluzole or a placebo during their chemotherapy. The goal is to see if riluzole reduces the severity of nerve-related symptoms like tingling, numbness, or pain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH Annecy-Genevois
Pringy, France
-
CH Beauvais
Beauvais, France
-
CHU de Clermont -Ferrand
Clermont-Ferrand, France
-
CHU de Dijon
Dijon, France
-
CHU de Reims
Reims, France
-
CHU de Saint-Etienne
Saint-Priest, France
-
Centre François Baclesse
Caen, France
-
Centre Georges François Leclerc
Dijon, France
-
Clinique St Côme
Compiègne, France
-
GHPSO
Creil, France
-
Hia Begin
Saint-Mandé, France
-
Hia Percy
Clamart, France
-
Hôpital Foch
Suresnes, France
-
ICO - Site Paul Papin
Angers, France
-
ICO - Site René Gauducheau
Saint-Herblain, France
-
Institut Jean Godinot
Reims, France
Conditions
Explore the condition pages connected to this study.